2. Polman CH, et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the

106

Bibliografia

1. McDonald WI, et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;

2. Polman CH, et al., Diagnostic criteria for multiple sclerosis: 2005 revisions to the

“McDonald Criteria”. Ann Neurol 2005;

3. Polman CH, et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol 2011;

4. Hafler DA. Multiple sclerosis J. Clin. Invest 2004;

5. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;

6. Jacobs LD, Cookfair DL, Rudick RA, et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;

7. G Protein-Coupled Receptors: Structure, Signaling, and Physiology, Cambridge University Press, 2010,

8. Multiple sclerosis: a comprehensive text, Elsevier Health Sciences, 2 luglio 2008, Molecules and Medicine, John Wiley & Sons, 2007.

9. David Rog, Multiple Sclerosis: Answers at Your Fingertips, Class Publishing Ltd, 1º aprile

2009, 121–.

107

10. Natural Product Chemistry for Drug Discovery, Royal Society of Chemistry, 15 gennaio 2010,

11. Martin Hofrichter, Industrial Applications, Springer, 28 ottobre 2010,

12. Roland Martin, Molecular Basis of Multiple Sclerosis: The Immune System, Springer, 29 settembre 2010,

13. Lydia P. Davenport, Stem cell research advances, Nova Biomedical Books, 2007.

14. Th 17 cells: role in inflammation and autoimmune disease, Springer, 2009

15. Comi G, et al., European/Canadian multicenter, double blind, randomized, placebo- controlled study of the effects of glatiramer acetate on magnetic resonance imaging- measured disease activity and burden in patients with relapsing multiple sclerosis. Ann

16. Tadini P., Martinelli V., Vilardo M. C. il farmacista e la sclerosi multipla Maya idee 2012

17. Steinman L. Immune therapy for autoimmune disease. Science 2004; 305:

18. Riassunto delle Caratteristiche del Prodotto IFN beta 1a

19. Riassunto delle Caratteristiche del Prodotto IFN beta 1b

20. Riassunto delle Caratteristiche del Prodotto Glatiramer

21. Riassunto delle Caratteristiche del Prodotto Fingolimod

22. Registri AIFA: http://aifa-neuro.agenziafarmaco.it/

23. Mario Raso, Trattato di anatomia patologica clinica, Piccin, 1986,

24. Giorgio Macchi, Malattie del Sistema Nervoso, 2, Piccin, 2005.

108

25. Nicola Canal, Angelo Ghezzi, Mauro Zaffaroni, Sclerosi multipla, 2, Elsevier, 2011

26. Ugo Nocentini, Sarah Di Vincenzo, La riabilitazione dei disturbi cognitivi nella sclerosi

27. Ugo Nocentini, Carlo Caltagirone, Gioacchino Tedeschi, I disturbi neuropsichiatrici nella

28. KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;

29. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann.Neurol. 2001;

30. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M et al.

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J.Neurol. 1997;

31. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP et al.

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;

32. Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K et al. Overview

of azathioprine treatment in multiple sclerosis. Lancet 1991;

109

33. Currier RD, Haerer AF, Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J.Neurol.Neurosurg.Psychiatry 1993;

34. Goodkin DE, Rudick RA, VanderBrug MS, Daughtry MM, Schwetz KM, Fischer J et al.

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann.Neurol. 1995;

35. Sorensen PS. The gap between effect of drugs and effectiveness of treatments. J.Neurol.Sci.

2007;

36. Multiple sclerosis. Clinical Guideline 8. Management of multiple sclerosis in primary and secondary care. 2003. National Insitute for Clinical Excellence.

37. Jeffery D, Bashir K, Buchwald L, Coyle P, Freedman M, Markowitz C et al. Optimizing immunomodulatory therapy for MS patients: an integrated management model.

J.Neurol.Sci. 2002;

38. Treatment optimization in multiple sclerosis: report of an international consensus meeting.

Eur.J.Neurol. 2004;

39. Flachenecker P. Disease-modifying drugs for the early treatment of multiple sclerosis.

Expert.Rev.Neurother. 2004;

40. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N.Engl.J.Med. 2000;

41. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH et al. Effect of early

versus delayed interferon beta-1b treatment on disability after a first clinical event

110

suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet.

2007;

42. Martinelli V, Comi G. Induction versus escalation therapy. Neurol.Sci. 2005;

43. Zaffaroni M, Ghezzi A, Comi G. Intensive immunosuppression in multiple sclerosis.

Neurol.Sci. 2006;

44. Wingerchuk DM, Noseworthy JH. Randomized controlled trials to assess therapies for multiple sclerosis. Neurology 2002;

45. Pachner AR, Steiner I. The multiple sclerosis severity score (MSSS) predicts disease severity over time. J.Neurol.Sci. 2009;

46. Weinshenker BG. Databases in MS research: pitfalls and promises. Mult.Scler. 1999;

47. Trojano M. Can databasing optimise patient care? J.Neurol. 2004;

48. Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G et al.

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult.Scler. 2006;

49. Flachenecker P, Stuke K. National MS registries. J.Neurol. 2008;

50. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;

51. Novantrone, Riassunto delle caratteristiche del prodotto. 2005.

52. FDA Food and Drug AdministrationEuropean Medicines Agency. Novantrone. Label and

Approval History.

111

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_

ApprovalHistory . 2-11-2009.

53. Bollettino di informazione sui farmaci. Bollettino di Informazione sui farmaci 2006;N.6 anno XIII.

54. Paolillo A, Pozzilli C, Giugni E, Tomassini V, Gasperini C, Fiorelli M et al. A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta. Eur.J.Neurol. 2002;

55. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. 2001;

56. Caon C, Din M, Ching W, Tselis A, Lisak R, Khan O. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur.J.Neurol. 2006;

57. Scott TF, Allen D, Price TR, McConnell H, Lang D. Characterization of major depression

symptoms in multiple sclerosis patients. J.Neuropsychiatry Clin.Neurosci. 1996;